Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, October 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet
twitter: 2 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 117 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,379 followers.

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. #lymphoma #lymsm https://t.co/OORwYw4max

New article: Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. https://t.co/9kALgJZW6w #AML #leusm #hematology

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.